ArticleThe Lancet regional health. Western Pacific2023
National and provincial burden of varicella disease and cost-effectiveness of childhood varicella vaccination in China from 2019 to 2049: a modelling analysis.
Article in The Lancet regional health. Western Pacific, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 35 citations in OpenAlex.
- Impact of immunization strategies, public health and social measures on the incidence of varicella among children aged 0-14 years in Quzhou City.Human vaccines & immunotherapeutics · 2026Article
- Vaccination coverage and influencing factors of four non‑National Immunization Program vaccines: A cross‑sectional survey among children aged 1‒6 years in Beijing, China.Human vaccines & immunotherapeutics · 2026Article
- Safety, immunogenicity, and effectiveness of the MAV/06 varicella vaccine: A comprehensive review of a new strain vaccine.Human vaccines & immunotherapeutics · 2026Review
- Article
- Article
- Varicella epidemiology, susceptibility and cost burden in Chongqing China: implications for prevention and control strategies.BMC infectious diseases · 2026Article
- Epidemiological characteristics of varicella in Xuzhou from 2015 to 2024: surveillance study.BMC infectious diseases · 2026Article
- The Impact and Effectiveness of a Two-Dose Varicella Immunization Program Among School Children: Evidence from Quasi-experimental Analyses.Infectious diseases and therapy · 2026Article
- Spatial-temporal patterns, seasonality, and age-specific trends of varicella in Hangzhou, China, 2019-2024.Frontiers in public health · 2026Article
- Epidemiological characteristics and incidence prediction of varicella from 2014 to 2023 in Chongqing, China.Frontiers in public health · 2026Article
- Parents' preference for the inclusion of pediatric vaccines in the Chinese National Immunization Program: A discrete choice experiment.Human vaccines & immunotherapeutics · 2025Article
- Paediatric varicella epidemiology in urban Beijing, China, 2014-2023.Emerging microbes & infections · 2025Article
- Article
- Validating the Predictions of a Dynamic Transmission Model Using Real-World Data from a Universal Varicella Vaccination Program in Germany.Journal of market access & health policy · 2025Article
- Effectiveness of a 2-dose varicella vaccination program in Changzhou, China, during the transitional period (2017-2022): a registry-based case-cohort study.BMC public health · 2025Article
- Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022.Vaccines · 2025Article
- Impact of natural and socio-economic factors on varicella incidence in children in Shanghai, 2013-2022.Frontiers in public health · 2025Article
- Epidemiological characteristics of breakthrough varicella cases among students in Jiulongpo District, Chongqing: implications for vaccination strategies.Frontiers in immunology · 2025Article
- Optimizing Varicella Vaccination Strategy: A Study on Age and Dose Impacts on Antibody Levels.Vaccines · 2024Article
- Public Preference and Priorities for Including Vaccines in China's National Immunization Program: Discrete Choice Experiment.JMIR public health and surveillance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In China, varicella is the third most frequently reported vaccine-preventable infectious disease after tuberculosis and influenza, and imposes a heavy burden on families and society. To inform future immunization policy, we investigated disease burden of varicella in China and explored cost-effectiveness of different varicella vaccination strategies at national and provincial levels. Methods: A dynamic transmission model was developed to assess disease burden of varicella and the impact of varicella vaccination in China. A cost-effectiveness analysis of three alternative vaccination strategies in China's National Immunization Program (NIP) compared with no vaccination was conducted. Scenario analyses and sensitivity analyses were performed to check the robustness of the results. Findings: It was estimated that 3.35 million new varicella cases occurred in 2019, more than three times of 982 thousand cases officially reported from National Notifiable Infectious Disease Surveillance System (NNIDSS). The under-reported rate was approximately 71%. The economic analysis revealed that from the societal perspective, the incremental cost-effectiveness ratio (ICER) for one dose of varicella vaccination in NIP was US$ 2357 per QALY at the national level and it was cost-effective in 22 of 31 provinces. The ICER for one dose varicella vaccination plus a mass catch-up for unvaccinated children aged 2-11 years old would be US$ -5260 per QALY, cost-saving at the national level. The one dose plus mass catch-up NIP strategy was also cost-saving in 24 of the 31 provinces. Interpretation: Varicella incident cases were substantially under-reported in China. Varicella vaccination in the NIP could significantly contribute to reducing the burden of varicella disease. From the societal perspective, including varicella vaccination into China's NIP was highly cost-effective at the national level and in most provinces. Funding: Bill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.